messaggio

clik on the image and visit the new site

New site clik on the image

"In silico"


From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.


Phage Therapy is influenced by:

Phage therapy is influenced by:

Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
Mutation rate
Phenotypical delay
Phage cocktail

My point of view

Tuesday, 14 December 2010

May an Outbreak of Cholera be stopped down by Bacteriophages?



CDC cholera

From this work:
(December 13, 2010)






Update: Outbreak of Cholera --- Haiti, 2010




Year 2005

"Self-limiting nature of seasonal cholera epidemics:Role of host-mediated amplification of phage"

Phage predation of Vibrio cholerae has recently been reported to be a factor that influences seasonal epidemics of cholera in Bangladesh.....

Year 2006

"Modeling the role of bacteriophage in the control of cholera outbreaks"

Year 2008

"Transmission of Vibrio cholerae Is Antagonized by Lytic Phage and Entry into the Aquatic Environment"

Year 2009

From:
"Cholera transmission: the host,pathogen and bacteriophage dynamic"

"For the years of 1928, 1929 and 1934,
totals of 36,000, 130,823 and 871,316 vibriophage doses were prepared and disseminated by the Inquiry staff at the time that outbreaks began in specific study communities in . Vibriophages were also disseminated into community drinking water sources for prophylaxis. The death rates from cholera were compared with control communities for before and after the interventions. The triennial death rates from cholera fell from 30 to 2 per 10,000 in regions that were treated with .
Although these studies had multiple limitations, they do provide the only available data for the efficacy of vibriophage therapy.
Advances in rehydration and antibiotic therapy in the 1930s and 1940s made bacteriophage trials based on mortality end points unethical and statistically challenging."